No Data
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Astria Therapeutics : Oppenheimer Cuts Target Price to $25 From $29